As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Jin Medical International Ltd. The largest reported stake is Novastralist Horizon Ltd.'s, at 10.46%. 3 filings are on record since August 18, 2026 (Schedule 13G, August 18, 2026).
Sell to companies like Jin Medical International Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Erqi Wang · Sole voting: 5,306,307 · Shared voting: 0 · Sole dispositive: 5,306,307 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-25
- · Holder: Wang Erqi · Percent: 6.77% · SCHEDULE 13D
- · Holder: Novastralist Horizon Ltd. · Percent: 10.46% · Shares: 7,702,376 · SCHEDULE 13G
Jin Medical International Ltd. has 3 Schedule 13D or 13G filings on record since 2026-08-18. 1 holder's latest filing reports 5% or more of class a ordinary shares, par value us$0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Novastralist Horizon Ltd. | 10.46% | 7,702,376 | SCHEDULE 13G, 2026-08-18 | 2026-08-18 |
| 3.35% | 5,306,307 | SCHEDULE 13D/A, 2026-09-25 | 2026-09-24 |
Holding shares or following this stake? See who's behind Jin Medical International Ltd. and the warning signs.
Free to see. No signup.
Watch Jin Medical International Ltd.
Get an email when Jin Medical International Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jin Medical International Ltd.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Jin Medical International Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jin Medical International Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Novastralist Horizon Ltd. | 7,702,376 | 0 | 7,702,376 | 0 | SCHEDULE 13G, 2026-08-18 |
| Chang Gil LEE | 7,702,376 | 0 | 7,702,376 | 0 | SCHEDULE 13G, 2026-08-18 |
| Erqi Wang | 5,306,307 | 0 | 5,306,307 | 0 | SCHEDULE 13D/A, 2026-09-25 |
| JOLLY HARMONY ENTERPRISES Ltd | 4,769,057 | 0 | 4,769,057 | 0 | SCHEDULE 13D/A, 2026-09-25 |
The latest filing identifies Jin Medical International Ltd. by CUSIP G5140V120 and gives its principal executive office as No. 33 Lingxiang Road, Wujin District, Changzhou City, Jiangsu Province (SCHEDULE 13D/A, 2026-09-25).
Source of funds (Item 3)
The information set forth in Item 5 is hereby incorporated by reference into this Item 3. Item 3 is hereby amended and supplemented in its entirety as follows: The transaction described in Item 5 involved an issuance of shares by the Issuer to certain third parties. The Reporting Persons were not parties to this transaction and did not provide any funds or other consideration.Erqi Wang, SCHEDULE 13D/A, 2026-09-25
Purpose of Transaction (Item 4)
Erqi Wang
The information set forth in Item 5 is hereby incorporated by reference into this Item 4. Item 4 is hereby amended and supplemented to add the following: This Amendment No. 1 is filed to report that the Reporting Persons' aggregate percentage beneficial ownership and voting power in the Issuer were diluted as a result of the Issuer's issuance of shares as described in Item 5 below.Item 4 of the SCHEDULE 13D/A filed 2026-09-25
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-18 | Novastralist Horizon Ltd. | 10.46% | SCHEDULE 13G |
| 2026-08-21 | Wang Erqi | 6.77% | SCHEDULE 13D |
| 2026-09-25 | Erqi Wang | 3.35% | SCHEDULE 13D/A |
Questions about who owns Jin Medical International Ltd.
Who owns Jin Medical International Ltd.?
On this page, one holder's latest ownership filing reports 5% or more of Jin Medical International Ltd.: Novastralist Horizon Ltd. (10.46%, Schedule 13G, filed 2026-08-18).
When did Novastralist Horizon Ltd. buy into Jin Medical International Ltd.?
The filings give report dates, not purchase dates. The earliest filing from Novastralist Horizon Ltd. on this page is the Schedule 13G, filed 2026-08-18, reporting 10.46%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Jin Medical International Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.